摘要
目前晚期非小细胞肺癌(NSCLC)靶向治疗有明显进步,表皮生长因子受体(EGFR)活性突变的晚期NSCLC患者给予酪氨酸激酶抑制剂成为治疗首选,不可避免地出现耐药现象,使得化疗仍然占有一席之地;同时没有EGFR活性突变的晚期NSCLC患者占大多数,对于这部分患者的治疗仍然是首选化疗。因此,化疗在晚期NSCLC治疗中仍然至关重要。本综述介绍了目前EGFR野生型晚期肺癌一线、二线治疗的选择,旨在减少治疗的盲目性。
Remarkable progress has been made in the targeted treatment of advanced non- small cell lung cancer（ NSCLC） over the past several years. Administration of tyrosine kinase inhibitor is the preferred treatment for advanced NSCLC patients with mutational epidermal growth factor receptor（ EGFR）, and thus chemotherapy remains a crucial method in the treatment of the disease due to the inevitable drug tolerance. Meanwhile,advanced NSCLC patients without mutational EGFR are in the majority,and chemotherapy is also the preferred treatment for these patients. Therefore,chemotherapy is still of paramount importance. This paper summarizes the treatment strategies for advanced NSCLC with wild- type EGFR in first- tier and second-tier hospitals in order to avoid blindness of treatment.
出处
《中国全科医学》
CAS
CSCD
北大核心
2015年第6期707-710,共4页
Chinese General Practice
关键词
癌
非小细胞肺
化疗
受体
表皮生长因子
Carcinoma
non-small-cell lung
Chemotherapy
Receptor
epidermal growth factor
